Add time:08/27/2019         Source:sciencedirect.com

ObjectiveDopamine supersensitivity psychosis (DSP) is one of the key factors contributing to the development of antipsychotic treatment-resistant schizophrenia (TRS). We investigated the efficacy of Blonanserin (cas 132810-10-7), an atypical antipsychotic, for patients with TRS and DSP.

We also recommend Trading Suppliers and Manufacturers of Blonanserin (cas 132810-10-7). Pls Click Website Link as below: cas 132810-10-7 suppliers